Related references
Note: Only part of the references are listed.Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments
Magdalena Misiak-Galazka et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review
Saifuddin Kharawala et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)
Characteristics of Japanese patients with pustulotic arthro-osteitis associated with palmoplantar pustulosis: a multicenter study
Toshiyuki Yamamoto et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Guselkumab for the treatment of palmoplantar pustulosis
Masamoto Murakami
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism
Masamoto Murakami et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2020)
Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis
T. Yamamoto et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations
Egidio Freitas et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2020)
Clinical and genetic differences between pustular psoriasis subtypes
Sophie Twelves et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2019)
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich et al.
JOURNAL OF DERMATOLOGY (2019)
Evaluation of the efficacy of granulocyte and monocyte adsorption apheresis on skin manifestation and joint symptoms of patients with pustulotic arthro-osteitis
Hiroshi Kawakami et al.
JOURNAL OF DERMATOLOGY (2019)
Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study
Shigetoshi Sano et al.
JOURNAL OF DERMATOLOGY (2018)
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2018)
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis A Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2018)
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway
Robert Bissonnette et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal
Michiyoshi Kouno et al.
JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients
H. Trattner et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
Isabelle M. Sanchez et al.
DERMATOLOGY AND THERAPY (2017)
Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: A prospective, randomized, left-right comparison study
Mayuko Muro et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Phase III clinical study of maxacalcitol ointment in patients with palmoplantar pustulosis: A randomized, double-blind, placebo-controlled trial
Yoshinori Umezawa et al.
JOURNAL OF DERMATOLOGY (2016)
Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database
Kiyoshi Kubota et al.
BMJ OPEN (2015)
Increased peripheral Th17 in patients with pustulosis palmaris et plantaris
Kan Torii et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
Efficacy of excimer light therapy (308 nm) for palmoplantar pustulosis with the induction of circulating regulatory T cells
Takuya Furuhashi et al.
EXPERIMENTAL DERMATOLOGY (2011)
Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum
Masamoto Murakami et al.
EXPERIMENTAL DERMATOLOGY (2011)
Pustulosis palmoplantaris is a disease distinct from psoriasis
Anne C. de Waal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2011)
Acrosyringium Is the Main Site of the Vesicle/Pustule Formation in Palmoplantar Pustulosis
Masamoto Murakami et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Share Paper
